Biblio

Author Title Type [ Year

]

Filters: Author is Gumin, Joy [Clear All Filters]

2023

Stitzlein LM, Gangadharan A, Walsh LM, Nam D, Espejo AB, Singh MM, Patel KH, Lu Y, Su X, Ezhilarasan R, et al. Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles. Front Neurol. 2023;14:1112207.

Kan P, Srinivasan VM, Gumin J, Garcia R, Chen SR, Johnson JN, Collins DE, Chen MM, Ledbetter D, Huse J, et al. Development of a Rabbit Human Glioblastoma Model for Testing of Endovascular Selective Intra-Arterial Infusion (ESIA) of Novel Stem Cell-Based Therapeutics. Neuro Oncol. 2023.

Zheng C, Wei Y, Zhang Q, Sun M, Wang Y, Hou J, Zhang P, Lv X, Su D, Jiang Y, et al. Multiomics analyses reveal /YBX1-controlled posttranscriptional circuits promoting glioblastoma tumorigenesis/radioresistance. Sci Adv. 2023;9(31):eadf3984.

McDonald MF, Hossain A, Momin E, Hasan I, Singh S, Adachi S, Gumin J, Ledbetter D, Yang J, Long L, et al. Tumor-specific Polycistronic miRNA Delivered by Engineered Exosomes for the Treatment of Glioblastoma. Neuro Oncol. 2023.

2021

Shimizu Y, Gumin J, Gao F, Hossain A, Shpall EJ, Kondo A, Kerrigan BCParker, Yang J, Ledbetter D, Fueyo J, et al. Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma. J Neurosurg. 2021:1-11.

2019

Srinivasan VM, Gumin J, Camstra KM, Chen SR, Johnson JN, Shimizu Y, Kerrigan BCParker, Shpall EJ, Lang FF, Kan P. Microcatheter delivery of neurotherapeutics: compatibility with mesenchymal stem cells. J Neurosurg. 2019:1-9.

Marisetty AL, Lu L, Veo BL, Liu B, Coarfa C, Kamal MMostafa, Kassem DHamada, Irshad K, Lu Y, Gumin J, et al. REST-DRD2 mechanism impacts glioblastoma stem cell-mediated tumorigenesis. Neuro Oncol. 2019.